文献速递药物相互作用特殊人群用药药物不良反应与药物警戒

妊娠期药物不良事件系统中药物相互作用致妊娠糖尿病信号检测的可靠性探索

Exploring the Reliability of Detecting Drug-Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems.
PubMed 文献 · Drug Saf · 2025-09-02

本研究基于WHO全球不良事件报告数据库VigiBase,使用omega不一致性测量对30种药物-药物-事件组合进行交互作用分析,聚焦抗精神病药或抗抑郁药与CYP450调节药物联用致妊娠糖尿病的潜在药代动力学相互作用。结果发现艾司西酞普兰、西酞普兰和舍曲林与CYP2D6抑制剂联用出现统计信号,但病例系列审查因用药时间不确定未能支持这些相互作用的存在。

要点

  • VigiBase中抗抑郁药与CYP2D6抑制剂联用出现妊娠糖尿病统计信号
  • 病例系列审查因用药时间不确定未能验证上述相互作用
  • 不良事件报告系统检测妊娠期药代动力学药物相互作用可靠性有限

核心结论

  • 妊娠期抗抑郁药与潜在相互作用药物之间的药物相互作用统计信号可被识别,但病例审查后未进一步确认。
  • 用药和事件时间的不确定性影响了结局的可靠性,提示需用详细报告数据验证信号并重视准确用药报告。

研究设计与样本

  • 基于VigiBase(WHO全球不良事件报告数据库)识别妊娠期用药相关报告。
  • 根据WHO药物标准化分组选择涉及抗精神病药或抗抑郁药代谢通路的CYP450同工酶的潜在相互作用药物。
  • 使用omega不一致性测量进行统计交互作用分析并纳入合并用药,共考虑30种药物-药物-事件组合,随后进行病例系列审查,评估由作者共识主观判定。

主要发现

  • 在30种药物-药物-事件组合中,艾司西酞普兰、西酞普兰和舍曲林与CYP2D6抑制剂同时使用出现统计信号,妊娠糖尿病相对报告率较高。
  • 病例系列审查因报告为合并用药的实际用药时间不确定,未支持这些药物相互作用的存在。

临床怎么用

  • 临床解读不良事件报告系统中的妊娠期药物相互作用信号时需谨慎,应结合详细用药时间信息验证。
  • 应重视妊娠期用药报告的准确性,以支持信号检测的可靠性。

局限性

  • 用药和事件时间的不确定性影响结局可靠性。
  • 评估由作者共识主观判定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adverse event reporting systems are an important source of safety signals for drug use in pregnancy, but their usefulness in the identification of potential drug-drug interactions (DDIs) remains unclear. OBJECTIVE: Our objective was to explore the reliability of signal detection for pharmacokinetic DDIs during pregnancy in adverse event reporting systems, focusing on potential interactions between antipsychotics (APs) or antidepressants (ADs) and drugs modifying cytochrome P450 (CYP450) activity, increasing the occurrence of gestational diabetes mellitus (GDM). METHODS: Reports related to the use of drugs during pregnancy were identified in VigiBase, the World Health Organization (WHO) global database of adverse event reports. Potential interacting drugs were selected based on WHO Drug Standardised Drug Groupings for CYP450 isoenzymes involved in the metabolic pathway of the AP or AD of interest. We conducted statistical interaction analysis using the omega disproportionality measure and including concomitant medication to identify potential DDIs, followed by a case series review for supporting evidence. Evaluation was subjective by author consensus. RESULTS: Of the 30 drug-drug-event combinations considered, statistical signals emerged for escitalopram, citalopram, and sertraline and the simultaneous use of CYP2D6 inhibitors with a higher relative reporting rate of GDM. However, case series review of reports did not support the existence of these DDIs because of uncertainties regarding the actual timing of medication use reported as concomitant. CONCLUSION: Statistical signals of DDIs between ADs and potential interacting drugs during pregnancy were identified but not pursued further after case reviews. Uncertainty around medication use and event timing affected the reliability of the outcomes. These findings highlight the need to validate signals using detailed report data and stress the importance of accurate medication reporting.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Robiyanto R, Barrett JW, Sandberg L, et al. Exploring the Reliability of Detecting Drug-Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems. Drug Saf. 2025. PMID: 40898004. doi:10.1007/s40264-025-01607-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。